Publication Date:
1982-09-17
Description:
Herpes simplex virus (HSV) exists in humans in a latent form that can be activated. To characterize the molecular basis of the cell-virus interactions and to analyze the state of the latent HSV genome, an in vitro model system was established. In this system a large fraction of the latently infected cells contain an HSV genome that can be activated. Cell survival was reduced minimally after repression of high multiplicity HSV type 1 (HSV-1) infection of human fibroblast cells with (E)-5-(2-bromovinyl)-2'-deoxyuridine in combination with human leukocyte interferon (IFN-alpha). A minimum of 1 to 3 percent of the surviving cells contained an HSV genome that could be activated either by human cytomegalovirus superinfection or reduction in incubation temperature.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Wigdahl, B L -- Scheck, A C -- De Clercq, E -- Rapp, F -- CA 09124/CA/NCI NIH HHS/ -- CA 18450/CA/NCI NIH HHS/ -- CA 27503/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 1982 Sep 17;217(4565):1145-6.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/6180477" target="_blank"〉PubMed〈/a〉
Keywords:
Bromodeoxyuridine/analogs & derivatives/therapeutic use
;
Cells, Cultured
;
Cytarabine/pharmacology
;
Herpes Simplex/*physiopathology/therapy
;
Humans
;
Interferons/therapeutic use
;
Simplexvirus/*physiology
;
Virus Activation
;
*Virus Replication/drug effects
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
